$GSK

GlaxoSmithKline (GSK) plans to close its Dresden vaccine plant by 2028, affecting 641 jobs. The closure is part of GSK's 'Accelerate Growth' cost-cutting program, aiming for £1.9 billion in annual savings by 2029. GSK's share price rose 6% after the announcement. The company cites falling demand and strategic redirection as reasons. The works council and union are developing a 'plan for the future' to explore alternatives.

GSK is advancing long-acting biologics and AI to treat respiratory diseases like COPD. Key programs include IL-33 and TSLP treatments, with pivotal studies planned. The company also explores opportunities in pulmonary hypertension and liver disease. GSK uses partnerships and AI to accelerate drug development, aiming to identify effective treatment combinations. According to GSK, COPD affects 300 million patients globally, with limited advanced therapies currently available.

GSK (GSK) presented its R&D strategy at the Bernstein healthcare forum, focusing on respiratory medicine, liver disease, and AI-driven drug development. The company highlighted opportunities in COPD, MASH, and pulmonary arterial hypertension, with a focus on de-risked biology and external partnerships. GSK shares closed at $49.71, down 1.99%, with a P/E ratio of 16.05 and a dividend yield of 3.5%.

GSK forecasts £40B sales, driven by oncology and specialty medicines, which now account for 40% of its business. The company aims to reduce costs by £1.9B while increasing R&D investment. Key products like Excentia and BLENREP face launch challenges, with updates expected in Q3. GSK also highlighted progress in hepatitis B treatment bepirovirsen and launches from its Nuvalent acquisition.

GSK outlined a growth strategy at the Bank of America Global Healthcare Conference, focusing on cost savings and investment in its pipeline, particularly in oncology. The company aims for over 7% sales growth and 11% profit growth from 2021 to 2026, with specialty products expected to exceed 50% of its business by 2031. GSK identified 1.9 billion pounds in savings, mostly for pipeline funding, and reiterated its strong balance sheet.

GSK plc is investing in pipeline growth and specialty medicines, which are expected to make up over 50% of its portfolio by 2031. The company's cost-saving program of GBP 1.9 billion is supporting this growth. Key drug launches and future opportunities in oncology are highlighted as significant factors for the company's growth, according to the company.

Nine European pharmaceutical giants, including Sanofi and AstraZeneca, urge Europe to boost competitiveness. They cite $600B in U.S. and China investments, warning of losing ground to global rivals. The companies highlight the sector's historical success and call for government action.

GSK directors bought shares, signaling confidence. Chair Sir Jonathan Symonds acquired 1,500 shares at £18.8110 each. Directors Elizabeth McKee Anderson and Charles Bancroft bought 626 and 1,734 ADS at $49.8534 each, respectively. Purchases may indicate positive outlook for the biopharmaceutical company.

European drugmakers, including AstraZeneca, GSK, and Novartis, called for increased government spending, faster trials, and stronger IP protections to compete with the US and China. They warned of a decline in Europe's pharmaceutical industry, citing a drop in R&D share and clinical trials. Europe spends 1% of GDP on pharmaceuticals, compared to 2% in the US and 1.8% in China. Industry experts highlight slower European policies as a concern for investment decisions.

GSK plans to invest £400 million in a new 300,000-square-foot R&D center at Cambridge Biomedical Campus, housing over 1,000 scientists. The facility will focus on areas like oncology and vaccines, with a phased move by 2029. GSK aims to strengthen its UK research network and collaborate with local life sciences clusters.